Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fepixnebart (LY3016859) in Chronic Low Back Pain
NCT04529096Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2020
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of Fepixnebart in chronic low back pain (CLBP), sponsored by Eli Lilly and Company. Started Aug 2020; status: completed.
02
Drugs
Fepixnebart
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT04529096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04529096.